Eton Announces Commercial Availability of IMPAVIDO Capsules
Eton Pharmaceuticals launched its U.S. commercial availability for IMPAVIDO (miltefosine) capsules. This expansion into Eton's rare disease infrastructure simplifies patient access through expanded support programs and a centralized pharmacy distribution network.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed